Analysts Offer Insights on Healthcare Companies: Neon Therapeutics Inc (NTGN) and Seres Therapeutics (MCRB)


There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Neon Therapeutics Inc (NTGN) and Seres Therapeutics (MCRB) with bullish sentiments.

Neon Therapeutics Inc (NTGN)

Oppenheimer analyst Kevin Degeeter maintained a Buy rating on Neon Therapeutics Inc today and set a price target of $20. The company’s shares opened today at $5.50, close to its 52-week low of $4.20.

Degeeter wrote:

“On 3/11/19, NTGN 1) reported uneventful 4Q18 financial results, 2) reiterated plans to present top-line data from NT-001 study in 1H19 and 3) updated timelines for communication of data from the NT-002 study and and NEO-PTC-01 CTA. Importantly, we believe NTGN is successfully protecting its first-mover advantage in personalized neoantigen product development with an oral presentation at AACR on relationships between immune response and clinical outcome for data on ten melanoma patients. Also, it plans to present the first long-term (52-week) follow-up from a large neoantigen study (NT-001) in 1H19 (potentially at ASCO).”

According to TipRanks.com, Degeeter is a 4-star analyst with an average return of 14.3% and a 52.3% success rate. Degeeter covers the Healthcare sector, focusing on stocks such as Catalyst Biosciences Inc, Molecular Templates Inc, and Genomic Health.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Neon Therapeutics Inc with a $20 average price target.

See today’s analyst top recommended stocks >>

Seres Therapeutics (MCRB)

In a report released today, Matthew Lillis from Cantor Fitzgerald maintained a Buy rating on Seres Therapeutics, with a price target of $13. The company’s shares opened today at $5.37.

Lillis commented:

“We believe MCRB is well positioned to translate discoveries of how the microbiome is involved in human physiology into proprietary therapeutics to treat important diseases. Development of clinical assets is likely to be impacted by the need to generate empirical data that may not be required for “typical” drug development. Thus, we believe investors might should view early-stage proof-of-concept (POC) or proof-of-biology (POB) data as more meaningful than might otherwise be the case. We believe SER-109 for treating C. diffiicle infection (CDI) and SER-287 for treating ulcerative colitis (UC) will be the main drivers of share value.”

According to TipRanks.com, Lillis is a 1-star analyst with an average return of -2.1% and a 33.3% success rate. Lillis covers the Healthcare sector, focusing on stocks such as Taiwan Liposome Company Ltd, Supernus Pharmaceuticals, and Evofem Biosciences Inc.

Currently, the analyst consensus on Seres Therapeutics is a Strong Buy with an average price target of $14, implying a 160.7% upside from current levels. In a report issued on March 6, Cowen & Co. also maintained a Buy rating on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts